Search clinical trials for: Physiologic saline - glucagon dummy

Total 5448 results

University Hospital Bispebjerg and Frederiksberg

Completed

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition (GLUCAGON)

Drug Overdose | Overdose of Beta-adrenergic Blocking Drug

Denmark
Steno Diabetes Center Copenhagen

Completed

Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Denmark
Steno Diabetes Center Copenhagen
University of Copenhagen

Completed

Hepatic Metabolic Changes in Response to Glucagon Infusion

Diabetes Mellitus | Non-Alcoholic Fatty Liver Disease | Total Pancreatectomy

Denmark
Zosano Pharma Corporation

Completed

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

Hypoglycemia

Australia
Steno Diabetes Center Copenhagen

Recruiting

Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes (The HYPO-AVOID)

Hypoglycemia | Type 1 Diabetes

Denmark
The University of Texas Health Science Center at...
South Texas Veterans Health Care System

Active, not recruiting

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism (Glucagon)

Insulin Sensitivity

United States
Xeris Pharmaceuticals
Empiristat, Inc.

Completed

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin Hypoglycemia

United States, Canada, Austria
Eli Lilly and Company

Completed

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company
Jaeb Center for Health Research; Locemia Solutions ULC

Completed

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Eli Lilly and Company
Locemia Solutions ULC

Completed

Evaluate the Immunogenicity of a Novel Glucagon Formulation

Diabetes Mellitus | Drug-specific Antibodies

Canada
Zealand Pharma

Completed

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Hypoglycemia

Germany
Eli Lilly and Company
Locemia Solutions ULC; T1D Exchange Clinic Network Coordinating Center

Completed

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

Diabetes Mellitus, Type 1

United States
Sanofi

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

Diabetes Mellitus

Japan
Charite University, Berlin, Germany

Unknown

Glucagon Modulation of Ghrelin Secretion

Obesity | Diabetes Mellitus, Type 1 | Healthy Subjects

Germany
Adocia

Completed

A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Type 1 Diabetes Mellitus

Germany
Steno Diabetes Center Copenhagen
Herlev Hospital; Technical University of Denmark

Completed

Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes (DHCL2021)

Type 1 Diabetes

Denmark
University of Copenhagen
Copenhagen University Hospital, Hvidovre

Recruiting

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Obesity

Denmark
Zealand Pharma
SynteractHCR

Completed

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Austria, Canada, Germany
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Hypoglycemia

United States
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

Hypoglycemia

United Kingdom
Fresenius Kabi USA, LLC

Completed

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

Hypoglycemia

United States
Université Catholique de Louvain
Fonds National de la Recherche Scientifique; BESPEED

Active, not recruiting

Phenotypic and Genotypic Characterization of New-onset Type I Diabetes (DIATAG)

Type1diabetes

Belgium
University of Maryland, Baltimore

Active, not recruiting

GLP-1 and Hypoglycemia

Type 2 Diabetes Mellitus

United States
University Hospital Tuebingen

Completed

Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge

Diabetes | Metabolic Syndrome

Germany
Hvidovre University Hospital

Completed

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Diabetes Mellitus Type 2

Denmark
Uppsala University
Karolinska Institutet

Completed

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans (GLPMOT)

Functional Gastrointestinal Disorders

Sweden
Cambridge University Hospitals NHS Foundation Trust

Completed

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers (COCOA)

Cardiovascular Diseases

United Kingdom
Sanofi

Withdrawn

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

Type 1 Diabetes Mellitus
Johns Hopkins University
Society of Critical Care Medicine

Terminated

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

Hypoglycemia | Critically Ill

United States
University Hospital, Gentofte, Copenhagen

Completed

Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone? (GLANCE)

Glucose Metabolism Disorders | Endocrine or Metabolic Disease

Denmark
Legacy Health System
Juvenile Diabetes Research Foundation; Oregon Health and Science University

Completed

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

Type 1 Diabetes Mellitus

United States
Oslo University Hospital

Completed

GLP-1 Effects on Insulin and Glucagon in PTDM

Post-transplant Diabetes Mellitus

Norway
Legacy Health System
Juvenile Diabetes Research Foundation; Oregon Health and Science University

Completed

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Hvidovre University Hospital

Completed

Beta-Cell Function After Near-Normalisation of Blood Glucose

Type 2 Diabetes

Denmark
Uppsala University
Karolinska Institutet; University of Copenhagen

Completed

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose (GIP-GLP-gas)

Physiology | Gastroenterology | Endocrinology

Sweden
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Healthy | Type 2 Diabetes Mellitus

United States
Xeris Pharmaceuticals

Completed

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Hypoglycemia

Canada
Inreda Diabetic B.V.

Withdrawn

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (STABLE-1)

Diabetes Mellitus, Type 1

Netherlands
Xeris Pharmaceuticals

Completed

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Canada
University of Aarhus

Completed

GLP-1 Infusion and Long-Time Fasting

Type 2 Diabetes

Denmark
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Mikkel Christensen

Completed

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus
Hvidovre University Hospital
Technical University of Denmark

Completed

The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Denmark
Cambridge University Hospitals NHS Foundation Trust
Antaros Medical

Recruiting

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes (COCONUT)

Obesity | Type 2 Diabetes

United Kingdom
Eli Lilly and Company
Locemia Solutions ULC

Completed

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (AMG102)

Hypoglycemia

Canada
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
University of Copenhagen
Hvidovre University Hospital

Completed

Investigation of GLP-2 Mechanism of Action (GA-8)

Healthy

Denmark

Search clinical trials for: Physiologic saline - glucagon dummy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations